Symptom-based liver enzyme and triglyceride testing is proposed for isotretinoin patients without risk factors to reduce ...

FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...

CAA 2026 mandates rebate pass-through and at least twice-yearly reporting on spread pricing, acquisition costs, and rebate amounts. Enforcement provisions include $10,000-per-day penalties for ...

IQVIA projects 118 U.S. biologics losing exclusivity by 2034 (~$234B opportunity), but only 12 had biosimilars in development as of Sept 2024, leaving most molecules uncontested. FDA draft guidance ...

Cohorts included 1,653 AL, 1,055 ATTRwt-CM, and 59 dual-diagnosis patients; only 53%–66% had any relevant test documented, and just 40%–49% had AL-specific workups. Complete monoclonal protein testing ...

In SYNCHRONIZE-MASLD (n=218), 84.2% on weekly survodutide 6.0 mg achieved ≥30% relative liver fat reduction versus 24.3% with placebo at week 48. Liver fat normalization occurred in ~61% of ...

This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable safety profile — and provides clinicians with actionable guidance on dose ...

Results from the DAPHNe trial point to ctDNA as having a role in guiding treatment, but the researchers and a commentator say more research needs to be done before determining exactly what it is.

Without savings from the 340B Drug Pricing Program as a lifeline, hospitals face service reductions or even closure.

This segment introduces the Phase III CROWN study, providing essential background on its design and framing the remarkable significance of reporting 7-year follow-up data in the setting of advanced, ...